(Q34413412)

2 August 2017

title

Design of humanized antibodies: from anti-Tac to Zenapax (English)

1 reference

2 August 2017

1 reference

Naoya Tsurushita

1

1 reference

2 August 2017

Paul R Hinton

series ordinal

2

1 reference

2 August 2017

Shankar Kumar

series ordinal

3

1 reference

2 August 2017

publication date

1 May 2005

1 reference

2 August 2017

1 reference

2 August 2017

volume

36

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

69-83

1 reference

Monoclonal antibodies market

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Engineering antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Replacing the complementarity-determining regions in a human antibody with those from a mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Reshaping human antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

A humanized antibody that binds to the interleukin 2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Monoclonal antibodies in the clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The formation of pyrrolid-2-one-5-carboxylic acid at the N-terminus of immunoglobulin G heavy chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Kabat Database and its applications: 30 years after the first variability plot

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

High-yield deblocking of amino termini of recombinant immunoglobulins with pyroglutamate aminopeptidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted structures, and observed antibody-antigen interactions in complexes of two antipeptide antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

NMR-derived model for a peptide-antibody complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

7 January 2021

The Protein Data Bank

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Using CLUSTAL for multiple sequence alignments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The human immunoglobulin VH repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Assembly of asparagine-linked oligosaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

V region carbohydrate and antibody expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Engineering antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Engineered antibodies with increased activity to recruit complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Engineered human IgG antibodies with longer serum half-lives in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Isotype can affect the fine specificity of an antibody for a polysaccharide antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Codon usage tabulated from international DNA sequence databases: status for the year 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Humanization and characterization of the anti-HLA-DR antibody 1D10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Internal ribosome entry site biology and its use in expression vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Properties and pharmacokinetics of two humanized antibodies specific for L-selectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Chimeric immunoglobulin light chains are secreted at different levels: influence of framework-1 amino acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Production of monoclonal antibodies in COS and CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Integrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The use of biosensor technology for the engineering of antibodies and enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Antibodies as therapeutic agents: vive la renaissance!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Humanization of a chicken anti-IL-12 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

Human antibody effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.007

10.1016/J.YMETH.2005.01.007

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference